PART I Overview We are a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases. We are focused on advancing melanocortin-4 receptor (MC4R) agonists, including our lead asset, IMCIVREE (setmelanotide), as precision medicines designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. While obesity affects hundreds of millions of people worldwide, we are developing therapies for a subse...
Q2 FY2026 — expected 2026-08-07
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001628280-26-012399 | EDGAR | 118K words |
| 2025-02-28 | 2024-12-31 | 0001558370-25-001889 | EDGAR | — |
| 2024-02-29 | 2023-12-31 | 0001558370-24-002181 | EDGAR | — |
| 2023-03-01 | 2022-12-31 | 0001558370-23-002613 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001558370-22-002543 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001558370-21-002121 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001558370-20-001896 | EDGAR | — |
| 2019-03-08 | 2018-12-31 | 0001558370-19-001698 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001558370-18-001923 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001104659-25-106264 | EDGAR | 74K words |
| 2025-08-05 | 2025-06-30 | 0001558370-25-010302 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0001558370-25-006765 | EDGAR | — |
| 2024-11-06 | 2024-09-30 | 0001558370-24-014532 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0001558370-24-011101 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-007076 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001558370-23-018291 | EDGAR | — |
| 2023-08-01 | 2023-06-30 | 0001558370-23-012739 | EDGAR | — |
| 2023-05-02 | 2023-03-31 | 0001558370-23-007675 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001558370-22-016818 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0001558370-22-011888 | EDGAR | — |
| 2022-05-03 | 2022-03-31 | 0001558370-22-006790 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-03 | 0001628280-26-023606 | EDGAR | 1K words |
| 2026-03-26 | 0001628280-26-021414 | EDGAR | — |
| 2026-03-20 | 0001628280-26-019995 | EDGAR | — |
| 2026-03-16 | 0001628280-26-018211 | EDGAR | — |
| 2026-03-02 | 0001104659-26-021801 | EDGAR | — |
| 2026-02-26 | 0001628280-26-011987 | EDGAR | — |
| 2026-01-09 | 0001628280-26-001459 | EDGAR | — |
| 2025-12-19 | 0001104659-25-123108 | EDGAR | — |
| 2025-12-11 | 0001104659-25-120141 | EDGAR | — |
| 2025-11-07 | 0001104659-25-108154 | EDGAR | — |
160 total filings indexed. 129 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001649904 |
| Ticker | RYTM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.rhythmtx.com |
| Listed | 2017-10-05 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report